Brain health

Neuromodulation & brain health.

Magnetic, electrical, acoustic and light stimulation of the brain, graded by evidence. What it can treat, where it fits in healthy aging, and where the data stop.

A tool for specific conditions, not an anti-aging device

Brain aging is shaped mostly by blood pressure, cholesterol, glucose, hearing, sleep, mood, activity and social life. The 2024 Lancet Commission links nearly half of dementia cases to 14 modifiable risk factors. Those come first.

Neuromodulation treats conditions that wear down brain function in later life: depression, chronic pain, post-viral cognitive symptoms and, in early trials, Alzheimer's disease. No trial shows that stimulating a healthy brain slows aging.

  1. 01

    Foundations

    Treat vascular and metabolic risk, hearing and vision; move, sleep, stay connected. Brain aging & cognitive reserve

  2. 02

    Diagnosis before devices

    New memory or mood symptoms need a work-up for reversible causes and a measured baseline.

  3. 03

    Targeted add-on

    Where a diagnosis fits the evidence, rTMS, TPS or other modalities as an add-on, with outcomes re-measured.

What each technique can honestly claim

Grades describe the best-supported use. The brain-aging column says what is known for aging, which is almost always less.

Evidence by neuromodulation modality: best-supported use, brain-aging evidence and further reading
Modality Best-supported use Brain aging Read more
rTMS Magnetic pulses induce currents in a targeted cortical region. Established for depression Brain aging: Alzheimer’s: one positive phase 2 RCT (precuneus). Emerging. Read the evidence on rTMS
TPS Ultrashort acoustic pressure pulses, MRI-navigated. Not focused ultrasound. Emerging Brain aging: CE-marked for Alzheimer’s in the EU; sham-controlled RCT missed its primary endpoint. Read the evidence on TPS
tDCS Weak direct current shifts cortical excitability. Moderate for depression Brain aging: Cognitive effects in healthy aging are inconsistent.
Gamma tACS / 40 Hz Rhythmic stimulation at 40 Hz, electrical or light-and-sound. Mouse data · human pilots Brain aging: Amyloid effects shown in mice; small human pilots in Alzheimer’s. Read the evidence on Gamma tACS / 40 Hz
VNS / taVNS Vagus nerve stimulation, implanted or through the ear. Established (implanted) · Emerging (taVNS) Brain aging: taVNS studied for inflammation and long COVID; no aging trials. Read the evidence on VNS / taVNS
Neurofeedback Real-time EEG feedback to train brain-activity patterns. Moderate for ADHD (debated) Brain aging: No aging-specific trials. Read the evidence on Neurofeedback
Photobiomodulation Near-infrared light aimed at mitochondrial metabolism. Emerging Brain aging: Extensive preclinical data; small early human trials. Read the evidence on Photobiomodulation
CES Microcurrent through ear-clip electrodes. Low-to-moderate certainty Brain aging: US clearance for anxiety and insomnia; no aging relevance shown.

Douwes Brain Center

Neuromodulation at St. George Hospital is delivered through the Douwes Brain Center, the hospital's brain-health service. Its own site describes the treatments and the clinical process.

Brain Health and Neuromodulation Guide

The physician's guide as a PDF: modalities, evidence grades, safety.

Get the free guide

All neuromodulation articles

49 articles

Transcranial Magnetic Stimulation (TMS) 7

Vagus Nerve Stimulation 6

Neurofeedback 4

PEMF Therapy 6

PEMF for Bone & Joint Health 2

Photobiomodulation 10

Brain Fog Treatment 4

Brain Aging 2

Cognitive Enhancement 1

Depression Causes 1

Depression Protocols 2

Ketamine Therapy 1

TMS Neuromodulation 1

TMS Therapy 2

The physician's guide to neuromodulation

What neuromodulation is

Neuromodulation uses magnetic, electrical, acoustic or light energy to change how specific brain circuits and nerves work. A medication acts on the whole body’s chemistry. Neuromodulation aims at a network: the dorsolateral prefrontal cortex in depression, the precuneus and default mode network in Alzheimer’s disease, the vagus nerve in epilepsy. Most techniques are non-invasive, and their effects build up over a course of sessions.

At St. George Hospital, neuromodulation is delivered through the Douwes Brain Center, our brain-health service, and is combined with the hospital’s other programmes for chronic illness, post-viral syndromes and cognitive decline.

Why it belongs in a conversation about healthy aging

Brain aging is driven by vascular health, metabolic health, inflammation, sleep, hearing, mood, activity and social life. The 2024 Lancet Commission estimates that nearly half of dementia cases are linked to 14 modifiable risk factors (Livingston 2024). Those are the foundations, and no device replaces them.

Neuromodulation enters at a different point. It is a tool for treating specific conditions that erode brain function in later life: depression, chronic pain, post-viral cognitive symptoms and, in early trials, Alzheimer’s disease. It is a symptomatic and functional treatment. It is not an anti-aging intervention, and no trial shows that stimulating a healthy brain slows aging. The full argument, with grades, is in brain aging and cognitive reserve.

How to read the grades on this page

  • Established: consistent evidence from randomised, sham-controlled trials and regulatory approval or clearance for the indication.
  • Moderate: positive randomised trials, but smaller, fewer or less consistent.
  • Emerging: early randomised data, pilots or mixed results. Reasonable to discuss as an add-on with informed consent.
  • Preliminary: mechanistic or animal data, or uncontrolled case series only.

The modalities

Transcranial magnetic stimulation (TMS / rTMS)

A coil over the scalp produces magnetic pulses that induce electrical currents in the cortex underneath. Repetitive TMS is FDA-cleared for treatment-resistant major depression, and deep TMS for OCD and smoking cessation. In a small double-blind RCT (n=29), an accelerated, MRI-targeted protocol (SAINT/SNT) produced remission in 78.6% of patients with treatment-resistant depression at four weeks, against 13.3% with sham (Cole 2022). The result is striking and the sample is small.

For brain aging, the strongest single trial is in Alzheimer’s disease: 24 weeks of rTMS over the precuneus slowed cognitive and functional decline compared with sham in 50 patients (Koch 2022), a single-centre phase 2 result awaiting replication.

Grade: Established for depression · Emerging for Alzheimer’s disease. Read more: TMS guide · TMS for depression · How rTMS works Douwes Brain Center ↗

Transcranial pulse stimulation (TPS)

TPS delivers single, ultrashort acoustic pressure pulses (about 3 microseconds) to brain regions mapped from the patient’s MRI. It is a shock-wave-type stimulus. It is not low-intensity focused ultrasound, which uses longer wave trains, and it is not magnetic stimulation.

The NEUROLITH TPS system has been CE-marked for Alzheimer’s disease in the EU since 2018; it is not FDA-cleared. The first clinical study, Beisteiner 2020, was an uncontrolled pilot in 35 patients that showed feasibility and pre-to-post improvement (Beisteiner 2020). The first sham-controlled RCT, published in 2025 with 60 patients, did not meet its primary cognitive endpoint (P = .68). Exploratory analyses suggested benefit in patients aged 70 or younger and improvement in depressive symptoms; both need confirmation (Matt 2025).

Grade: Emerging (CE-marked for Alzheimer’s in the EU; RCT evidence mixed). Read more: TPS: what the evidence shows

Transcranial direct current stimulation (tDCS)

A weak direct current (typically 1 to 2 mA) through scalp electrodes shifts cortical excitability. In a fully remote, sham-controlled phase 2 trial, home-based tDCS improved depressive symptoms (Woodham 2025). On 8 December 2025 the FDA approved Flow Neuroscience’s FL-100, a home-use tDCS device for depression (premarket approval P230024). Evidence for cognitive benefit in healthy aging is inconsistent.

Grade: Moderate for depression · Preliminary for cognitive enhancement.

Transcranial alternating current and 40 Hz “gamma” stimulation (tACS, sensory)

Rhythmic stimulation at 40 Hz reduced amyloid and changed microglia in mice (Iaccarino 2016). In people with Alzheimer’s disease, small pilots of gamma tACS and of 40 Hz light-and-sound stimulation reported changes in memory scores, perfusion and atrophy (Benussi 2021; Chan 2022).

Grade: Preclinical → early human pilots (Emerging at best).

Vagus nerve stimulation (VNS and taVNS)

Implanted VNS is FDA-approved for drug-resistant epilepsy and treatment-resistant depression. Transcutaneous auricular VNS (taVNS) stimulates the auricular branch of the vagus through the ear and is being studied for inflammation, long COVID, migraine and mood. Trials are small and protocols vary.

Grade: Established for implanted VNS in epilepsy · Emerging for taVNS. Read more: Vagus nerve stimulation · Vagus nerve and inflammation

Neurofeedback and qEEG

Real-time EEG feedback trains people to change their own brain-activity patterns; quantitative EEG (qEEG) maps those patterns. Results depend heavily on protocol, and effects tend to look smaller in blinded comparisons than in open studies.

Grade: Moderate for ADHD (debated) · Emerging elsewhere. Read more: qEEG brain mapping · Neurofeedback vs biofeedback

Transcranial photobiomodulation (PBM)

Near-infrared light absorbed by mitochondrial cytochrome c oxidase is proposed to improve cellular energy metabolism and blood flow. Preclinical data are extensive; controlled human trials are small and early.

Grade: Emerging. Read more: Transcranial photobiomodulation

Pulsed electromagnetic field therapy (PEMF)

PEMF devices have long been FDA-cleared for non-union fractures. Evidence for pain and other uses is fragmented and of mixed quality.

Grade: Established for bone healing · Mixed elsewhere. Read more: PEMF therapy

Cranial electrotherapy stimulation (CES)

Low-level alternating microcurrent through ear-clip electrodes. In the US, CES devices are cleared for anxiety and insomnia; claims for depression fall under stricter premarket rules. The trials are small and heterogeneous.

Grade: Low-to-moderate certainty (small, heterogeneous trials).

Evidence summary

ModalityBest-supported useBrain-aging relevanceGrade
rTMSTreatment-resistant depressionPrecuneus rTMS in Alzheimer’s (one phase 2 RCT)Established (depression) · Emerging (AD)
TPSAlzheimer’s add-on (CE-marked, EU)Sham-controlled RCT missed primary endpoint; age ≤70 signalEmerging
tDCSDepressionCognitive effects inconsistentModerate (depression)
Gamma tACS / 40 Hz sensoryNone establishedMouse data; human pilotsEmerging at best
VNS / taVNSEpilepsy, TRD (implanted)taVNS studied for inflammation and long COVIDEstablished (implanted) · Emerging (taVNS)
NeurofeedbackADHD (debated)No aging-specific trialsModerate · Emerging
PhotobiomodulationNone establishedEarly human dataEmerging
CESAnxiety, insomnia (US clearance)NoneLow-to-moderate certainty

How the right modality is chosen

A neuromodulation plan starts with a diagnosis, not a device:

  1. Clinical assessment and history, including reversible causes of cognitive or mood symptoms (thyroid, B12, medications, sleep apnoea, depression).
  2. Neurocognitive testing to set a baseline that can be re-measured.
  3. qEEG or imaging where it changes the decision.
  4. Matching the modality to the indication and the evidence, then re-measuring after the course so that a non-response is recognised.

Safety and who it is not for

Non-invasive neuromodulation is generally well tolerated. Typical effects are scalp discomfort or headache with TMS and skin irritation under tDCS electrodes. Seizures with TMS are rare and screened for.

Neuromodulation is not for:

  • Healthy people seeking anti-aging or enhancement. No trial supports it.
  • Anyone with new cognitive symptoms who has not been assessed. Diagnosis comes first.
  • People with modality-specific contraindications, for example certain metal or electronic implants near the coil (TMS), skull defects or bleeding risk in the treatment path (TPS), or uncontrolled epilepsy. The treating centre should screen in writing.

The honest bottom line

Neuromodulation is one of the most interesting areas of brain medicine, and some of it is established care. For brain aging specifically, the evidence is early: one positive phase 2 trial for rTMS in Alzheimer’s disease, one sham-controlled TPS trial that missed its primary endpoint, and pilots for gamma stimulation. That is enough to offer some of these treatments as add-ons with clear informed consent. It is not enough to sell them as a way to keep a healthy brain young.

For a broader overview of the techniques, the Douwes Brain Center maintains a guide to non-invasive neuromodulation Douwes Brain Center ↗.

References

  1. Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024. PMID: 39096926
  2. Cole EJ, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022. PMID: 34711062
  3. Koch G, et al. Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial. Brain. 2022. PMID: 36281767
  4. Beisteiner R, et al. Transcranial pulse stimulation with ultrasound in Alzheimer’s disease: a new navigated focal brain therapy. Adv Sci (Weinh). 2020. PMID: 32042569
  5. Matt E, et al. Ultrasound neuromodulation with transcranial pulse stimulation in Alzheimer disease: a randomized clinical trial. JAMA Netw Open. 2025. PMID: 40009384
  6. Woodham RD, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med. 2025. PMID: 39433921
  7. Iaccarino HF, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016. PMID: 27929004
  8. Benussi A, et al. Exposure to gamma tACS in Alzheimer’s disease: a randomized, double-blind, sham-controlled, crossover, pilot study. Brain Stimul. 2021. PMID: 33762220
  9. Chan D, et al. Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: results of feasibility and pilot studies. PLoS One. 2022. PMID: 36454969

New brain-health research, graded honestly

Email only, no medical details needed. Privacy policy.